{"link": "http://hdl.handle.net/10138/135715", "subject": "farmaceustik Kemi', 'farmaceustik Kemi", "wordcount": 25384, "major": "Pseudopeptides and Peptidomimetics Modulating the Proteolytic Activity of Kallikrein-related Peptidase 3", "abstract": "The highly prostate specific serine protease kallikrein-related peptidase 3 (KLK3, also known as prostate specific antigen, PSA) is widely used as a biomarker for prostate cancer and it has also been postulated that it may play a part in tumour growth. Especially interestesting is the antiangiogenic effect exerted by proteolytically active KLK3 in cell line models. In order to stimulate the proteolytic activity of KLK3, a series of peptides have been developed by phage display methodology. Even though the peptides are quite potent KLK3 stimulators, they are not directly suitable for in vivo studies or use as drugs. \\n\\nEven though there are many natural and unnatural biologically active peptides, they suffer from rapid clearance via the liver and kidneys and proteolytic degradation of the compounds both in the gastrointestinal tract and other parts of the body. This gives peptides a poor oral bioavailability meaning that they are usually administered as intravenous or intramuscular injections. Several different strategies have been developed in order to access compounds with improved bioavailability including modifications of the peptide structure, development of pseudopeptides and development of small molecular weight peptidomimetics. \\n\\nThis thesis concentrates on the further development of the two most potent peptides known to stimulate KLK3, i.e. B-2 and C-4. The main part of the work was concentrated on the replacement of disulphide bridges in the peptides in order to both gain more information on which residues are necessary for obtaining the biological activity and at the same time also gain information on how changes to the geometry of the disulphide bridge affects the activity. \\n\\nA series of different disulphide bridge mimicking building blocks were designed and synthesised with the intention of using them in a protocol for solid-phase synthesis of KLK3 stimulating peptides. Unfortunately, the use of these building blocks in the synthesis of pseudopeptides based on C-4 turned out to be an unsurmountable challenge and the synthesis had to be completed using a different strategy in which the key step was the use of ring-closing metathesis (RCM) for the cyclisation of the partly completed pseudopeptide. Pleasingly, the synthesis of pseudopeptide analogues of the B-2 peptide using the building blocks was more successful. In total three pseudopeptide analogues of C-4 and four of B-2 were synthesised and shown to retain the biological activity of the parent peptides. \\n\\nBased on the information from the synthesised pseudopeptides and a molecular modelling study, a 4-quinolone based peptidomimetic was designed to mimic the C-4 peptide and a synthetic protocol was devised to access this compound. Even though the synthesis of the desired target compound has so far not been successful, the synthetic protocol that was designed has given access to a number of 1,2,8-trisubstituted 4-quinolone derivatives.', 'Prostatacancer \u00e4r i nul\u00e4get den vanligaste formen av cancer hos m\u00e4n i v\u00e4stv\u00e4rlden, s\u00e5 mycket som var sj\u00e4tte man har uppskattats insjukna i den under sin livstid. \u00c4ven om d\u00f6dligheten ber\u00e4knas till endast n\u00e5gra procent inneb\u00e4r den stora utbredningen att prostatacancer orsakar det n\u00e4st h\u00f6gsta antalet d\u00f6dsfall i cancer hos m\u00e4n efter lungcancer. Pga detta \u00e4r det viktigt att hitta nya metoder b\u00e5de f\u00f6r att bota prostatacancer och f\u00f6r att sakta ner sjukdomsf\u00f6rloppet. \\n\\nKallikrein 3 (human kallikrein-related peptidase 3, KLK3; \u00e4ven k\u00e4nd som prostataspecifik antigen, PSA) \u00e4r ett prostataspecifikt enzym som klyver proteiner och peptider (en proteas). KLK3 uts\u00f6ndras i s\u00e4desv\u00e4tskan och dess biologiska uppgift \u00e4r att klyva de gelbildande proteiner som uts\u00f6ndras vid ejakulation. Enzymatiskt aktivt KLK3 har visat sig inhibera tillv\u00e4xten av blodk\u00e4rl b\u00e5de in vitro och in vivo vilket har antagits bidra till en l\u00e5ngsammare tum\u00f6rtillv\u00e4xt. En elakartad tum\u00f6r i prostatan s\u00e4nker uts\u00f6ndringen av KLK3 i epitelv\u00e4vnaden j\u00e4mf\u00f6rt med en frisk prostata. KLK3 inverkar p\u00e5 tum\u00f6rtillv\u00e4xten i prostatacancer genom att p\u00e5verka de proteolytiska kaskaderna som bryter ned den extracellul\u00e4ra matrisen och d\u00e4rmed inhibera tum\u00f6rtillv\u00e4xten. Substanser som g\u00f6r det m\u00f6jligt att modifiera den proteolytiska aktiviteten hos KLK3 \u00e4r mycket intressanta f\u00f6r utvecklingen av nya l\u00e4kemedel mot prostatacancer. \\n\\nEn serie peptider som stimulerar den proteolytiska aktiviteten hos KLK3 har tidigare utvecklats vid Helsingfors universitet. \u00c4ven om dessa peptider uppvisar en stark stimulerande effekt p\u00e5 KLK3 s\u00e5 s\u00f6nderfaller de snabbt i plasma, de har ocks\u00e5 en f\u00f6rh\u00e5llandevis stor molekylmassa f\u00f6r att vara peptider vilket starkt begr\u00e4nsar deras anv\u00e4ndbarhet in vivo. Studier har p\u00e5visat vilka delar av dessa peptider som \u00e4r viktiga f\u00f6r den biologiska aktiviteten, utg\u00e5ende fr\u00e5n denna information har vi syntetiserat serier med modifierade peptider f\u00f6r att vidare s\u00f6ka utreda vilka modifikationer som \u00e4r m\u00f6jliga att g\u00f6ra utan att den biologiska aktiviteten sjunker avsev\u00e4rt. F\u00f6rhoppningen \u00e4r att dessa modifikationer ocks\u00e5 f\u00f6rb\u00e4ttrar peptidernas stabilitet in vitro och in vivo. De tv\u00e5 mest aktiva av de k\u00e4nda peptiderna valdes ut och de naturliga disulfidbryggorna i dessa ersattes med en kolv\u00e4tekedja samtidigt som andra, mindre f\u00f6r\u00e4ndringar, gjordes i \u00f6vriga delar av peptiden. Vissa av peptiderna i dessa serier visade sig ha en klar biologisk aktivitet som dock var n\u00e5got l\u00e4gre \u00e4n den hos ursprungspeptiderna. En viktig slutsats av studien var att inga omfattande f\u00f6r\u00e4ndringar i peptidens struktur \u00e4r m\u00f6jliga. \\n\\nDet slutliga m\u00e5let med projektet var att utveckla sm\u00e5molekyler med en biologisk effekt som motsvarar den hos de ursprungliga peptiderna. Information fr\u00e5n studierna av peptiderna och de modifierade peptiderna i kombination med datorbaserad molekylmodellering gjorde att vi valde att anv\u00e4nda ett 1,2,8-trisubstituerat 4-kinolonskelett som grund f\u00f6r dessa peptidmimetika och ett syntesprotokoll f\u00f6r s\u00e5dana substanser utvecklades. Detta syntesprotokoll visade sig vara generellt till\u00e4mpbart och anv\u00e4ndes till att syntetisera en serie 1,2,8-trisubstituerade 4-kinoloner med variation i struktur och egenskaper. De syntetiserade substanserna studeras f\u00f6r tillf\u00e4llet f\u00f6r sin KLK3-stimulerande effekt.", "faculty": "farmasia", "charcount": 150231, "commonwords": [["peptide", 231], ["synthesis", 185], ["peptides", 169], ["chem", 150], ["also", 126], ["klk3", 113], ["activity", 100], ["using", 93], ["compounds", 88], ["reaction", 83], ["structure", 75], ["different", 73], ["pseudopeptides", 72], ["biological", 71], ["acid", 70], ["prostate", 69], ["not", 64], ["cancer", 63], ["disulphide", 60], ["bond", 54]], "keywords": "", "unit": "farmasian tiedekunta', 'Helsingfors universitet, farmaceutiska fakulteten', 'University of Helsinki, Faculty of Pharmacy, Division of Pharmaceutical Chemistry and Technology", "status": "doctor", "thesistype": "V\u00e4it\u00f6skirja (artikkeli)', 'Doctoral dissertation (article-based)', 'Doktorsavhandling (sammanl\u00e4ggning)', 'Text", "pagecount": 93, "title": "Pseudopeptides and Peptidomimetics Modulating the Proteolytic Activity of Kallikrein-related Peptidase 3", "language": "en", "author": "Meinander, Kristian", "date": "2014-08-28", "distinctwords": 5653}